secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quantum Cyber N.V. (QUCY)
CIK:        0001874252
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001213900-26-044125
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mainz Biomed sells next-gen CRC screening IP for $1.25M, updates Nasdaq equity compliance
--------------------------------------------------------------------------------

- Entered asset purchase agreement to sell Next Gen IP for $1.25M; closing by April 23, 2026.
- Proceeds to be used for settlement of outstanding liabilities and general corporate purposes.
- Continues development of pancreatic cancer detection product and explores post-quantum cybersecurity.
- Believes stockholders' equity exceeds $2.5M after receiving $6M total from preferred share sale (Feb & March 2026).
- Previously wound down ColoAlert product and next-gen colorectal cancer screening development in Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1874252/000121390026044125/0001213900-26-044125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1874252/000121390026044125/ea0286510-8k_mainz.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-044125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer